Ekso Bionics (Nasdaq: EKSO), manufacturer of the Ekso Indego Personal exoskeleton, reported lower revenue numbers for its second quarter in a July 28 earnings call.
“While there was abnormal weakness in the second quarter, in large part due to what we believe are short-term delays in completing some multi-device enterprise health sales, we are working to get back on track for the second half of the year and beyond,” said Scott Davis, Ekso Bionics’ CEO in the earnings call presentation. “In addition to pulling in those aforementioned sales deferrals and continuing to meet anticipated enterprise health customer demand, we expect that to be bolstered by an increasing contribution from our personal health products, which grew by more than 50% year over year in the first half of 2025.”
Ekso Bionics reported revenue of $2.1 million in its second quarter. Earnings for the same period in 2024 were $5 million. The difference, the company said, was “partially offset by higher Ekso Indego Personal device sales.”
Gross profit for the second quarter 2025 was $0.8 million with a gross margin of approximately 40%. For the same period last year, the company reported a gross profit of $2.6 million with a gross margin of 53%.
In February, Ekso Bionics announced it had signed a partnership with National Seating & Mobility (NSM) that made NSM the exclusive distributor of the Ekso Indego Personal exoskeleton within the Complex Rehab Technology industry. In April 2024, the Centers for Medicare & Medicaid Services announced Medicare coverage for personal exoskeletons.
In its presentation, Ekso Bionics’ statistics showed an approximately $2 billion personal mobility exoskeleton market currently obtainable via Medicare and Veterans Affairs (VA) funding for people with spinal cord injuries. Adding private-pay insurance for people with spinal cord injuries would expand that obtainable market to approximately $3.5 billion.
But expanding personal mobility exoskeleton use to clients with neurodegenerative diagnoses — including multiple sclerosis, Parkinson’s disease, and amyotrophic lateral sclerosis — would create a potential addressable market of $13.1 billion. And expanding exoskeleton use to include clients who use manual wheelchairs, including seniors, due to general mobility-related disabilities expands the exoskeleton market size to potentially $34 billion.
Ekso Bionics’ statistics referred to expansion into the neurodegenerative space as “potential future” and the “general debility” space as “long-term potential future.”
